Skip to Main Content

WASHINGTON — A powerful Democratic committee chair is starting to work on a new drug pricing package, rather than advancing an existing bill — an onerous effort, but one that may be Democrats’ best hope for substantive action this Congress.

Senate Finance Committee Chair Ron Wyden (D-Ore.), a longtime advocate of drug pricing reform, said he will take on the unenviable task of working to build a drug pricing package that can get unanimous support among his Democratic colleagues, rather than pushing ahead with a more aggressive House proposal or a more modest, bipartisan package he painstakingly crafted over years. President Biden called on lawmakers to pass Medicare drug price negotiation this year, and if they are going to succeed, a major factor will be Wyden’s ability to craft a consensus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.